Healthcare provider profile · identity verified

Roberto Miranda Guzman, M.D.

General Practice · ARECIBO, PR · NPI 1295906204

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Famotidine	Famotidine	361	148
Losartan Potassium	Losartan Potassium	245	74
Rosuvastatin Calcium	Rosuvastatin Calcium	241	78
Simvastatin	Simvastatin	233	66
Gabapentin	Gabapentin	223	75
Synthroid	Levothyroxine Sodium	222	60
Metformin Hcl	Metformin Hcl	217	65
Alendronate Sodium	Alendronate Sodium	183	62
Amlodipine Besylate	Amlodipine Besylate	181	54
Lisinopril	Lisinopril	179	49
Omeprazole	Omeprazole	171	53
Atorvastatin Calcium	Atorvastatin Calcium	169	59
Baclofen	Baclofen	164	125
Montelukast Sodium	Montelukast Sodium	152	66
Hydrochlorothiazide	Hydrochlorothiazide	142	48
Clonazepam	Clonazepam	129	26
Diclofenac Sodium	Diclofenac Sodium	116	91
Fluticasone Propionate	Fluticasone Propionate	113	70
Metoprolol Succinate	Metoprolol Succinate	113	39
Nabumetone	Nabumetone	109	86
Tamsulosin Hcl	Tamsulosin Hcl	105	36
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	86	31
Cephalexin	Cephalexin	83	72
Albuterol Sulfate Hfa	Albuterol Sulfate	81	32
Glimepiride	Glimepiride	80	22
Finasteride	Finasteride	68	21
Dexamethasone	Dexamethasone	64	56
Meloxicam	Meloxicam	64	38
Sertraline Hcl	Sertraline Hcl	64	15
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	63	46
Pioglitazone Hcl	Pioglitazone Hcl	63	21
Pantoprazole Sodium	Pantoprazole Sodium	62	22
Irbesartan	Irbesartan	61	19
Enalapril Maleate	Enalapril Maleate	59	12
Ezetimibe	Ezetimibe	57	21
Glipizide	Glipizide	57	21
Clopidogrel	Clopidogrel Bisulfate	56	21
Pentoxifylline	Pentoxifylline	56	19
Latanoprost	Latanoprost	55	12
Metoprolol Tartrate	Metoprolol Tartrate	50	15
Levofloxacin	Levofloxacin	46	41
Donepezil Hcl	Donepezil Hcl	45	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	43	12
Sucralfate	Sucralfate	41	18
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	39	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Prednisone	Prednisone	38	30
Fenofibrate	Fenofibrate Nanocrystallized	37	12
Naproxen Sodium	Naproxen Sodium	36	33
Temazepam	Temazepam	36	suppressed
Meclizine Hcl	Meclizine Hcl	34	17
Azithromycin	Azithromycin	33	33
Glyburide	Glyburide	33	12
Dicyclomine Hcl	Dicyclomine Hcl	31	31
Memantine Hcl	Memantine Hcl	31	suppressed
Buspirone Hcl	Buspirone Hcl	30	suppressed
Furosemide	Furosemide	30	11
Wixela Inhub	Fluticasone Propion/Salmeterol	30	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	28	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	27	24
Carvedilol	Carvedilol	27	suppressed
Alprazolam	Alprazolam	26	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	26	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	26	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	26	24
Methylprednisolone	Methylprednisolone	25	21
Oxybutynin Chloride	Oxybutynin Chloride	25	suppressed
Spironolactone	Spironolactone	25	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Farxiga	Dapagliflozin Propanediol	24	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	22	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	21
Metoclopramide Hcl	Metoclopramide Hcl	22	22
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Eliquis	Apixaban	21	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	21	20
Cilostazol	Cilostazol	19	suppressed
Flecainide Acetate	Flecainide Acetate	19	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Fluorometholone	Fluorometholone	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	17	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	16	suppressed
Divalproex Sodium	Divalproex Sodium	16	suppressed
Gemfibrozil	Gemfibrozil	16	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	16	suppressed
Synjardy	Empagliflozin/Metformin Hcl	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Lorazepam	Lorazepam	15	suppressed
Lumigan	Bimatoprost	15	suppressed
Fluconazole	Fluconazole	14	14
Sure Comfort	Syringe And Needle,insulin,1ml	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Jentadueto	Linagliptin/Metformin Hcl	13	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	13	13
Lamotrigine	Lamotrigine	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Novolog	Insulin Aspart	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Tramadol Hcl	Tramadol Hcl	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	11
Humalog	Insulin Lispro	12	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	12	suppressed
Topiramate	Topiramate	12	suppressed
Atenolol	Atenolol	11	suppressed
Diltiazem Hcl	Diltiazem Hcl	11	suppressed
Glipizide Er	Glipizide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error